图为2020年1月30日在瑞士巴塞尔拍摄的瑞士制药商罗氏公司总部标志。
The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020.
10月23日——Zymeworks于周五表示，罗氏已通过一项总额最高达8.13亿美元的全球许可协议，获得了开发和商业化其实验性肺癌药物的权利。
Oct 23 - Zymeworks said on Friday Roche has gained rights to develop and commercialize its experimental lung cancer drug under a global licensing deal worth up to $813 million.
Zymeworks将获得5500万美元的首付款，并在该瑞士制药商启动计划中的该药物剂量优化研究时获得额外的4000万美元。在Zymeworks完成一项正在进行的早期研究的剂量递增部分后，罗氏将接管该疗法的开发。该公司表示，该药物靶向DLL3，这是一种常见于小细胞肺癌细胞但在健康组织中罕见的蛋白质。Zymeworks首席执行官肯尼斯·加尔布雷思对路透社表示，由于“我们三特异性T细胞接合器平台的创新性和差异化”，罗氏在疗效数据出来之前就同意就ZW209开展合作。
加尔布雷思称，预计将于2026年底前入组首位患者。该公司表示，除了未来销售的分级特许权使用费外，它还可能获得高达7.18亿美元的开发、监管和商业里程碑付款。
Zymeworks will receive $55 million upfront and an additional $40 million when the Swiss drugmaker begins a planned dose-optimization study of the drug ZW209 Roche will take over the development of the treatment after Zymeworks completes the dose-escalation portion of an ongoing early-stage study The company said the drug targets DLL3, a protein commonly found on small-cell lung cancer cells but rarely seen in healthy tissue Roche has agreed to partner on ZW209 before efficacy data were available because of "the innovation and differentiation in our trispecific T-cell engager platform," Zymeworks CEO Kenneth Galbraith told Reuters The first patient is expected to be enrolled before the end of 2026, Galbraith said The company said it could receive up to $718 million in development, regulatory and commercial milestone payments, in addition to tiered royalties on future sales